ALOGLIPTIN BENZOATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C18H21N5O2.C7H6O2
Molecular Weight	461.5139
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cn1c(=O)cc(N2CCC[C@]([H])(C2)N)n(Cc3ccccc3C#N)c1=O.c1ccc(cc1)C(=O)O

InChI

InChIKey=KEJICOXJTRHYAK-XFULWGLBSA-N

InChI=1S/C18H21N5O2.C7H6O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19;8-7(9)6-4-2-1-3-5-6/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3;1-5H,(H,8,9)/t15-;/m1./s1

HIDE SMILES / InChI

Molecular Formula	C18H21N5O2
Molecular Weight	339.3923
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	C7H6O2
Molecular Weight	122.1216
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022271s009lbl.pdf
Curator's Comment:: description was created based on several sources, including https://www.takeda.com/news/2013/20130924_5997.html; http://www.ncbi.nlm.nih.gov/pubmed/22651127; http://www.ncbi.nlm.nih.gov/pubmed/17441705

Alogliptin (trade name Nesina in the US and Vipidia in Europe) is an orally administered anti-diabetic drug in the DPP-4 inhibitor class, discovered by Takeda Pharmaceutical Company's wholly owned subsidiary, Takeda San Diego, Inc. (former Syrrx) which was acquired by Takeda in 2005. Alogliptin does not decrease the risk of heart attack and stroke. Like other members of the gliptin class, it causes little or no weight gain, exhibits relatively little risk of causing hypoglycemia, and exhibits relatively modest glucose-lowering activity. Alogliptin and other gliptins are commonly used in combination with metformin in patients whose diabetes cannot adequately be controlled with metformin alone.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Dipeptidyl peptidase 4 8 Target ID: P27487 Gene ID: 1803.0 Gene Symbol: DPP4 Target Organism: Homo sapiens (Human) Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022271s009lbl.pdf	Inhibitor 7728

Conditions

Condition	Modality	Targets	Highest Phase	Product
Type 2 diabetes mellitus 240 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022271s009lbl.pdf	Secondary		Approved 8043	NESINA Approved Use Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitation of Use: Not for treatment of type 1 diabetes or diabetic ketoacidosis. Launch Date 1.35907194E12

C_max

Value	Dose	Analyte	Population
165 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25936384/	25 mg 1 times / day steady-state, oral dose: 25 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	[NO STEREO] ALOGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
154.83 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663	25 mg 1 times / day multiple, oral dose: 25 mg route of administration: oral experiment type: multiple co-administered:	ALOGLIPTIN plasma	Homo sapiens population: healthy age: Adults sex: food status:
335.36 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663	50 mg 1 times / day multiple, oral dose: 50 mg route of administration: oral experiment type: multiple co-administered:	ALOGLIPTIN plasma	Homo sapiens population: healthy age: Adults sex: food status:
75.38 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663	12.5 mg 1 times / day multiple, oral dose: 12.5 mg route of administration: oral experiment type: multiple co-administered:	ALOGLIPTIN plasma	Homo sapiens population: healthy age: Adults sex: food status:
114.08 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663	25 mg single, oral dose: 25 mg route of administration: oral experiment type: single co-administered:	ALOGLIPTIN plasma	Homo sapiens population: healthy age: Adults sex: food status:
246 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663	50 mg single, oral dose: 50 mg route of administration: oral experiment type: single co-administered:	ALOGLIPTIN plasma	Homo sapiens population: healthy age: Adults sex: food status:
55.28 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663	12.5 mg single, oral dose: 12.5 mg route of administration: oral experiment type: single co-administered:	ALOGLIPTIN plasma	Homo sapiens population: healthy age: Adults sex: food status:

AUC

Value	Dose	Analyte	Population
1511 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25936384/	25 mg 1 times / day steady-state, oral dose: 25 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	[NO STEREO] ALOGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1174.76 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663	25 mg single, oral dose: 25 mg route of administration: oral experiment type: single co-administered:	ALOGLIPTIN plasma	Homo sapiens population: healthy age: Adults sex: food status:
1625.58 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663	25 mg 1 times / day multiple, oral dose: 25 mg route of administration: oral experiment type: multiple co-administered:	ALOGLIPTIN plasma	Homo sapiens population: healthy age: Adults sex: food status:
2488.48 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663	50 mg single, oral dose: 50 mg route of administration: oral experiment type: single co-administered:	ALOGLIPTIN plasma	Homo sapiens population: healthy age: Adults sex: food status:
3389.21 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663	50 mg 1 times / day multiple, oral dose: 50 mg route of administration: oral experiment type: multiple co-administered:	ALOGLIPTIN plasma	Homo sapiens population: healthy age: Adults sex: food status:
601.65 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663	12.5 mg single, oral dose: 12.5 mg route of administration: oral experiment type: single co-administered:	ALOGLIPTIN plasma	Homo sapiens population: healthy age: Adults sex: food status:
842.17 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663	12.5 mg 1 times / day multiple, oral dose: 12.5 mg route of administration: oral experiment type: multiple co-administered:	ALOGLIPTIN plasma	Homo sapiens population: healthy age: Adults sex: food status:
1674.87999999999 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663	25 mg single, oral dose: 25 mg route of administration: oral experiment type: single co-administered:	ALOGLIPTIN plasma	Homo sapiens population: healthy age: Adults sex: food status:
3306.68 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663	50 mg single, oral dose: 50 mg route of administration: oral experiment type: single co-administered:	ALOGLIPTIN plasma	Homo sapiens population: healthy age: Adults sex: food status:
895.28 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663	12.5 mg single, oral dose: 12.5 mg route of administration: oral experiment type: single co-administered:	ALOGLIPTIN plasma	Homo sapiens population: healthy age: Adults sex: food status:

T_1/2

Value	Dose	Analyte	Population
16.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25936384/	25 mg 1 times / day steady-state, oral dose: 25 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	[NO STEREO] ALOGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
21 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022271s011lbl.pdf	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	[NO STEREO] ALOGLIPTIN plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
20.67 h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663	12.5 mg single, oral dose: 12.5 mg route of administration: oral experiment type: single co-administered:	ALOGLIPTIN plasma	Homo sapiens population: healthy age: Adults sex: food status:
19.45 h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663	25 mg single, oral dose: 25 mg route of administration: oral experiment type: single co-administered:	ALOGLIPTIN plasma	Homo sapiens population: healthy age: Adults sex: food status:
17 h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663	50 mg single, oral dose: 50 mg route of administration: oral experiment type: single co-administered:	ALOGLIPTIN plasma	Homo sapiens population: healthy age: Adults sex: food status:

F_unbound

Value	Dose	Co-administered	Analyte	Population
80% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022271s011lbl.pdf	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:		[NO STEREO] ALOGLIPTIN plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
800 mg single, oral Highest studied dose Dose: 800 mg Route: oral Route: single Dose: 800 mg Sources: https://pubmed.ncbi.nlm.nih.gov/18405789	healthy, 26.6 years (range: 18-55 years) n = 5 Health Status: healthy Age Group: 26.6 years (range: 18-55 years) Sex: M Population Size: 5 Sources: https://pubmed.ncbi.nlm.nih.gov/18405789	Sources: https://pubmed.ncbi.nlm.nih.gov/18405789
400 mg 1 times / day steady, oral Highest studied dose Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18405788/	unhealthy, 55.6 years (range: 18 - 75 years) n = 16 Health Status: unhealthy Condition: type 2 diabetes Age Group: 55.6 years (range: 18 - 75 years) Sex: M+F Population Size: 16 Sources: https://pubmed.ncbi.nlm.nih.gov/18405788/	Other AEs: Headache, Dizziness... Other AEs: Headache (6 patients) Dizziness (4 patients) Constipation (3 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/18405788/
25 mg 1 times / day steady, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: steady Dose: 25 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000MedRedt2.pdf Page: p. 48	unhealthy, adult n = 6626 Health Status: unhealthy Age Group: adult Population Size: 6626 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000MedRedt2.pdf Page: p. 48	Disc. AE: Acute myocardial infarction, Angina unstable... AEs leading to discontinuation/dose reduction: Acute myocardial infarction (8 patients) Angina unstable (2 patients) Myocardial infarction (12 patients) Abdominal pain (2 patients) Diarrhea (1 patient) Nausea (3 patients) Edema peripheral (4 patients) Blood creatinine increased (6 patients) Creatinine renal clearance abnormal (3 patients) Creatinine renal clearance decreased (22 patients) Lipase increased (10 patients) Hyperglycemia (3 patients) Dizziness (4 patients) Headache (2 patients) Renal impairment (13 patients) Rash (2 patients) Rash pruritic (3 patients) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000MedRedt2.pdf Page: p. 48

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1601	inhibitor 1604 inducer 355	inhibitor 1702 substrate 1118	inhibitor 1475

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1383 CYP2C8 818 CYP2C19 1325 CYP3A4/5 241 OAT1 554 OAT3 588 OCT2 594	P-gp 1400 OAT1 294 OAT3 305 OCT2 316	CYP1A2 637 CYP2B6 501 CYP2C19 269 CYP3A4/5 108

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP1A2 1532	inducer 1440 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000ClinPharmR.pdf#page=166 Page: 166.0	little or no
CYP2B6 884	inducer 1440 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000ClinPharmR.pdf#page=166 Page: 166.0	little or no
CYP2C19 1392	inducer 1440 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000ClinPharmR.pdf#page=166 Page: 166.0	little or no
CYP2C9 1648	inducer 1440 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000ClinPharmR.pdf#page=166 Page: 166.0	little or no
CYP3A4/5 293	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000ClinPharmR.pdf#page=165 Page: 165.0	no [IC50 78 uM]	no (co-administration study) Comment: mechanism-based inhibition using midazolam; did not change in vivo 3A4 substrates (midazolam and atorvastatin exposure) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000ClinPharmR.pdf#page=165 Page: 165.0
CYP1A2 1532	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000ClinPharmR.pdf#page=165 Page: 165.0	no
CYP2C19 1392	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000ClinPharmR.pdf#page=165 Page: 165.0	no
CYP2C8 865	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000ClinPharmR.pdf#page=165 Page: 165.0	no
CYP2C9 1648	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000ClinPharmR.pdf#page=165 Page: 165.0	no
OAT1 558	inhibitor 3045 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136081/	no
OAT3 590	inhibitor 3045 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136081/	no
OCT2 595	inhibitor 3045 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136081/	no
CYP2D6 1738	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000ClinPharmR.pdf#page=165 Page: 165.0	some [IC50 >100 uM]	weak (co-administration study) Comment: increased dextromethorphan AUC by 26% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000ClinPharmR.pdf#page=165 Page: 165.0
CYP3A4/5 293	inducer 1440 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000ClinPharmR.pdf#page=166 Page: 166;62	yes	no (co-administration study) Comment: induction at 100 µM was 27.6% as effective as rifampin; did not affect exposure of 3A4 substrates (midazolam and atorvastatin) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000ClinPharmR.pdf#page=166 Page: 166;62

Drug as victim

Target	Modality	Activity	Clinical evidence
P-gp 1400	substrate 3113 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000ClinPharmR.pdf#page=166 Page: 166151.0	inconclusive	no (co-administration study) Comment: cyclosporin does not have significant impact on plasma PK of SYR-322 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000ClinPharmR.pdf#page=166 Page: 166151.0
OAT1 294	substrate 3113 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136081/	no
OAT3 305	substrate 3113 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136081/	no
OCT2 316	substrate 3113 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136081/	no
CYP2D6 1118	substrate 3113 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000ClinPharmR.pdf#page=164 Page: 164.0	yes
CYP3A4 1601	substrate 3113 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000ClinPharmR.pdf#page=164 Page: 164.0	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1507	inhibitor 1489 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000PharmR.pdf#page=109 Page: 109.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:72323	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:72323
ChemicalBook	CB91011068	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB91011068
MolPort	MolPort-005-933-065	https://www.molport.com/shop/molecule-link/MolPort-005-933-065
Selleck Chemicals	alogliptin-syr-322	http://www.selleckchem.com/products/alogliptin-syr-322.html
ZINC	ZINC000014961096	http://zinc15.docking.org/substances/ZINC000014961096
eMolecules	31229135	https://www.emolecules.com/cgi-bin/more?vid=31229135

PubMed

Title	Date	PubMed
Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.	2007 May 17	17441705
Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase IV.	2008	19075765
Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.	2008 Apr	18393107
(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors.	2008 Apr	18223196
Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes.	2008 Dec	19046129
Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis.	2008 Oct 27	18954434
Overview of the gliptin class (dipeptidyl peptidase-4 inhibitors) in clinical practice.	2009 Jan	19179812
Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study.	2009 Jan	19125992
The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice.	2009 Jan 14	19038243
A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure.	2009 Jul 17	19427871
A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease.	2009 Jul 20	19619327
Alogliptin: a new addition to the class of DPP-4 inhibitors.	2009 Jul 21	21437125
Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice.	2009 Jun	19371350
DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy.	2009 Mar	19259628
Diabetes treatment.	2009 Mar	19246581
Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes.	2009 Mar 1	19217790
Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice.	2009 May	19208898
Clinical pharmacology of alogliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of Type 2 diabetes.	2009 Nov	22112254
Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies.	2009 Nov	19793357
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.	2009 Oct	19650752
Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants.	2009 Oct	19622714
The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone.	2009 Sep	19478198
Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.	2009 Sep 28	19780719
Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.	2009 Sep-Oct	19801361
New therapeutic horizons: mapping the future of glycemic control with incretin-based therapy.	2009 Sep-Oct	19783765
Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy.	2010	21701614
Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat).	2010	20652060
Recommendations for management of diabetes during Ramadan: update 2010.	2010 Aug	20668157
Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.	2010 Aug	20590741
Managing type 2 diabetes in the primary care setting: beyond glucocentricity.	2010 Aug	20571352
DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes.	2010 Dec	20843518
The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review.	2010 Jan	20082581
The evolving place of incretin-based therapies in type 2 diabetes.	2010 Jul	20130920
Synthesis of a novel analogue of DPP-4 inhibitor Alogliptin: Introduction of a spirocyclic moiety on the piperidine ring.	2010 Jul 1	20703380
The physiologic role of incretin hormones: clinical applications.	2010 Mar	20382839
Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/db mice.	2010 Mar	20151999
Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk.	2010 Mar 24	20448799
New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin.	2010 May 10	21437082
Alogliptin: a novel molecule for improving glycemic control in type II diabetes mellitus.	2010 Nov	20879969
Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes.	2010 Nov	20724648
DPP-4 inhibitors: what may be the clinical differentiators?	2010 Nov	20708812
Alogliptin: a review of its use in the management of type 2 diabetes mellitus.	2010 Oct 22	20883057
Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.	2010 Sep	20690781
Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment.	2010 Sep 7	20859539
Exenatide once weekly: clinical outcomes and patient satisfaction.	2010 Sep 7	20859458
Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.	2012 Aug 1	22686547
Novel pyrrolopyrimidine analogues as potent dipeptidyl peptidase IV inhibitors based on pharmacokinetic property-driven optimization.	2012 Jun	22475866

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dose in patients with normal renal function or mild renal impairment is 25 mg once daily. Can be taken with or without food. Adjust dose if moderate or severe renal impairment or end-stage renal disease (ESRD).

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Sat Jun 26 09:49:32 UTC 2021` Edited by `admin` on `Sat Jun 26 09:49:32 UTC 2021`
Record UNII	EEN99869SC
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ALOGLIPTIN BENZOATE

Official Name

English

ALOGLIPTIN BENZOATE [ORANGE BOOK]

Common Name

English

ALOGLIPTIN BENZOATE [MI]

Common Name

English

ALOGLIPTIN BENZOATE [USAN]

Common Name

English

ALOGLIPTIN BENZOATE COMPONENT OF KAZANO

Brand Name

English

SYR 322

Code

English

2-((6-((3R)-3-AMINOPIPERIDIN-1-YL)-3-METHYL-2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL)METHYL)BENZONITRILE MONOBENZOATE

Systematic Name

English

ALOGLIPTIN BENZOATE [MART.]

Common Name

English

ALOGLIPTIN BENZOATE [VANDF]

Common Name

English

ALOGLIPTIN BENZOATE [JAN]

Common Name

English

ALOGLIPTIN BENZOATE [WHO-DD]

Common Name

English

OSENI COMPONENT ALOGLIPTIN BENZOATE

Brand Name

English

ALOGLIPTIN BENZOATE COMPONENT OF OSENI

Brand Name

English

ALOGLIPTIN (AS BENZOATE)

Common Name

English

SYR-322

Code

English

BENZONITRILE, 2-((6-((3R)-3-AMINO-1-PIPERIDINYL)-3,4-DIHYDRO-3-METHYL-2,4-DIOXO-1(2H)-PYRIMIDINYL)METHYL)-, MONOBENZOATE

Systematic Name

English

KAZANO COMPONENT ALOGLIPTIN BENZOATE

Brand Name

English

2-((6-((3R)-3-AMINO-1-PIPERIDINYL)-3,4-DIHYDRO-3-METHYL-2,4-DIOXO-1(2H)- PYRIMIDINYL)METHYL)BENZONITRILE MONOBENZOATE

Systematic Name

English

NESINA

Brand Name

English

Classification Tree Code System Code

NCI_THESAURUS

C98086